See What HealthDay Can Do For You
Contact Us

Depressive Disorders Up With Antimuscarinics for OAB

Increased risk for women with overactive bladder syndrome receiving antimuscarinics

patient and a doctor in the office

WEDNESDAY, April 12, 2017 (HealthDay News) -- Women with overactive bladder (OAB) syndrome treated with antimuscarinics have increased subsequent risk of depressive disorder, according to a study published online April 5 in the Journal of Clinical Pharmacology.

Shiu-Dong Chung, Ph.D., M.D., from the Far Eastern Memorial Hospital in Taiwan, and colleagues conducted a retrospective cohort study to examine the correlation between antimuscarinic use and subsequent risk of depressive disorder. Data were obtained from the Taiwan Longitudinal Health Insurance Database 2005 for 1,952 women with OAB who received antimuscarinics and 9,760 who did not receive antimuscarinics. The women were followed for three years from the index date.

The researchers found that the adjusted hazard ratio for depressive disorder was 1.38 (95 percent confidence interval, 1.15 to 1.64) for women with OAB who received antimuscarinics versus those who did not receive antimuscarinics. For women with OAB aged 18 to 39, 40 to 59, and ≥60 years who received antimuscarinics, the adjusted hazard ratios for subsequent depressive disorder were 1.83 (95 percent confidence interval, 1.27 to 2.64), 1.36 (95 percent confidence interval, 1.03 to 1.81), and 1.16 (95 percent confidence interval, 0.86 to 1.56), respectively.

"Clinicians should be alert to the relationship between antimuscarinics usage and depressive disorder in OAB women and provide appropriate instructions for these patients," the authors write.

Full Text

Physician's Briefing